These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9646302)

  • 1. Anabolic agents in trauma and sepsis: repleting body mass and function.
    Saito H
    Nutrition; 1998 Jun; 14(6):554-6. PubMed ID: 9646302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone and IGF-I therapy in the hypercatabolic patient.
    Wolf SE; Barrow RE; Herndon DN
    Baillieres Clin Endocrinol Metab; 1996 Jul; 10(3):447-63. PubMed ID: 8853450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats.
    Meyer NA; Barrow RE; Herndon DN
    J Trauma; 1996 Dec; 41(6):1008-12. PubMed ID: 8970554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive human growth hormone therapy in nutrition support: potential to limit septic complications in intensive care unit patients.
    Ziegler TR; Leader I
    Semin Respir Infect; 1994 Dec; 9(4):240-7. PubMed ID: 7886321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbed anabolic hormonal patterns in burned patients: the relation to glucagon.
    Nygren J; Sammann M; Malm M; Efendic S; Hall K; Brismar K; Ljungqvist O
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):491-500. PubMed ID: 7586625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor 1 has beneficial effects, whereas growth hormone has limited effects on postoperative protein metabolism, gut integrity, and splenic weight in rats with chronic mild liver injury.
    Inaba T; Saito H; Fukushima R; Hashiguchi Y; Lin MT; Inoue T; Fukatsu K; Muto T; Oka T; Takenaka A; Takahashi S; Noguchi T
    JPEN J Parenter Enteral Nutr; 1997; 21(2):55-62. PubMed ID: 9084006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The GH/IGF-1 system in critical illness.
    Elijah IE; Branski LK; Finnerty CC; Herndon DN
    Best Pract Res Clin Endocrinol Metab; 2011 Oct; 25(5):759-67. PubMed ID: 21925076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired growth hormone resistance in patients with hypercatabolism.
    Bentham J; Rodriguez-Arnao J; Ross RJ
    Horm Res; 1993; 40(1-3):87-91. PubMed ID: 7507879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.
    Kupfer SR; Underwood LE; Baxter RC; Clemmons DR
    J Clin Invest; 1993 Feb; 91(2):391-6. PubMed ID: 7679407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of growth hormone and insulin-like growth factor 1 (IGF-1) treatments on the nitrogen metabolism and hepatic IGF-1-messenger RNA expression in postoperative parenterally fed rats.
    Inaba T; Saito H; Fukushima R; Hashiguchi Y; Lin MT; Inoue T; Fukatsu K; Muto T; Takenaka A; Takahashi S; Noguchi T
    JPEN J Parenter Enteral Nutr; 1996; 20(5):325-31. PubMed ID: 8887900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and splanchnic metabolic response to exogenous human growth hormone.
    Dahn MS; Lange MP
    Surgery; 1998 May; 123(5):528-38. PubMed ID: 9591005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone and insulin-like growth factor I augment bactericidal capacity of human polymorphonuclear neutrophils.
    Inoue T; Saito H; Matsuda T; Fukatsu K; Han I; Furukawa S; Ikeda S; Muto T
    Shock; 1998 Oct; 10(4):278-84. PubMed ID: 9788660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with GH and IGF-1 in critical illness.
    Teng Chung T; Hinds CJ
    Crit Care Clin; 2006 Jan; 22(1):29-40, vi. PubMed ID: 16399018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone, burns and tissue healing.
    Lal SO; Wolf SE; Herndon DN
    Growth Horm IGF Res; 2000 Apr; 10 Suppl B():S39-43. PubMed ID: 10984252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome.
    Lieberman SA; Butterfield GE; Harrison D; Hoffman AR
    J Clin Endocrinol Metab; 1994 Feb; 78(2):404-10. PubMed ID: 7508949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone impaired compensation of hemorrhagic shock after trauma and sepsis in swine.
    Unneberg K; Balteskard L; Mjaaland M; Revhaug A
    J Trauma; 1996 Nov; 41(5):775-80. PubMed ID: 8913203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination.
    Hazel SJ; Gillespie CM; Moore RJ; Clark RG; Jureidini KF; Martin AA
    Kidney Int; 1994 Jul; 46(1):58-68. PubMed ID: 7933849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
    Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
    Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages and disadvantages of GH/IGF-I combination treatment.
    Janssen JA
    Rev Endocr Metab Disord; 2009 Jun; 10(2):157-62. PubMed ID: 18604645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of insulin-like growth factor-I and growth hormone in models of parenteral nutrition.
    Ney DM
    JPEN J Parenter Enteral Nutr; 1999; 23(6 Suppl):S184-9. PubMed ID: 10571453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.